Portal de Periódicos da CAPES

Low-Dose Triamcinolone Acetonide in the Phytocosmetic Lichtena^® Reduces Inflammation in Mild to Moderate Atopic Dermatitis

2005; Karger Publishers; Volume: 211; Issue: 4 Linguagem: Inglês

10.1159/000088504

1421-9832

Carolina Pellanda, Monika Weber, Andreas J. Bircher, Christian Surber,

Food Allergy and Anaphylaxis Research

<i>Background:</i> Previously, we reported the efficacy of Lichtena^® – a phytocosmetic cream product – in atopic dermatitis (AD). Later, fraudulent triamcinolone acetonide (TACA) was detected at low doses (16–40 µg/g) in Lichtena. This suggested that TACA may be effective at much lower concentrations than used in commercial products (1,000 µg/g). <i>Objectives:</i> To investigate the efficacy in AD of low-dose TACA in Lichtena compared to plain Lichtena. <i>Methods:</i> Fourteen patients presenting symmetrical lesions of AD were treated for 1 month with Lichtena plus 25 µg/g TACA (= verum) and plain Lichtena (= placebo). The severity of the lesions was assessed by the Severity Scoring of Atopic Dermatitis (SCORAD) on days 0 (= baseline), 7, 14 and 28. <i>Results:</i> Already after 1 week of treatment, significant SCORAD differences to baseline were observed comparing verum- and placebo-treated areas. No improvement was observed using plain Lichtena. <i>Conclusions:</i> TACA displayed a significant improvement of AD at doses up to 40 times lower than in commercial products.